MOLECULAR MECHANISMS OF FIBROBLAST GROWTH FACTOR IN HEPATO-CELLULAR CARCINOMA
AbstractHepatocellular carcinoma (HCC) is a widespread and lethal cancer type that affects people worldwide. Growth factor signalling pathways are critical in non-alcoholic fatty acid liver disease (NAFLD) and HCC as they activate a cascade of events that disrupt normal liver function. Therefore, these pathways offer a promising therapeutic strategy for NAFLD associated HCC. Several studies have found that fibroblast growth factor (FGF) levels are increased in patients with HCC. The FGF family comprises 22 proteins that can be classified as paracrine, intracrine, or endocrine factors. Most FGFs transmit signals through transmembrane tyrosine kinase FGF receptors. The main FGF in HCC progression includes: FGF8, FGF19 and FGF21, holds potential for HCC treatment. The FGF inhibitors: Lenvatinib, H3B-6527, BLU9931, CXF-009 and FGF401 have shown promising effects, yet our knowledge against HCC is limited. This review summarizes recent research in types of FGF, FGF signalling and FGF inhibitors as therapeutic targets in HCC.
Article Information
1
3129-3140
738 KB
502
English
IJPSR
Bhavya Dhawan, Uma Sharma and Sangeetha Gupta *
Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida, Uttar Pradesh, India.
sgupta23@amity.edu
29 April 2024
12 July 2024
24 October 2024
10.13040/IJPSR.0975-8232.15(11).3129-40
01 November 2024
Download